

10/039,059 Applicant Copy 7

PTO/SB/08 (2-92)

Sheet 1 of 4

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 313632000801

Application Number 10/039,059

Applicant

Ton LOGTENBERG and Cornelis Andriaan DE KRUIF

5-17-04

Filing Date December 31, 2001

Group Art Unit 9946 1636

Mailing Date May 23, 2002

RECEIVED

COPY OF PAPERS  
ORIGINALLY FILED

JUN 11 2002

## U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
AA2	1.	12/1994	5,374,548	Caras	424	450	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
AA2	2.	Abken, H. <i>et al.</i> "Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?" <i>Trends [in] Immunology Today</i> (January 1998) 19(1):2-5
	3.	Abken, H. <i>et al.</i> "Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumor cells," <i>Cancer Treatment Reviews</i> (1997) 23:97-112
	4.	Bennett, S. R. M. <i>et al.</i> "Help for cytotoxic-T-cell responses is mediated by CD40 signalling," <i>Nature</i> (4 June 1998) 393:478-480, <i>Letters to Nature</i>
	5.	Berd, D. <i>et al.</i> "Autologous, Hapten-Modified Vaccine as a Treatment for Human Cancers," <i>Seminars in Oncology</i> (December 1998) 25(6):646-653
	6.	Boder, E. T. <i>et al.</i> "Yeast surface display for screening combinatorial polypeptide libraries," <i>Nature Biotechnology</i> (June 1997) 15:553-557
	7.	Brocker, T. <i>et al.</i> "New simplified molecular design for functional T cell receptor," <i>Eur J Immunol</i> (1993) 23:1435-1439
	8.	De Kruif, J. <i>et al.</i> "Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes," <i>FEBS Letters</i> (1996) 399:232-236
	9.	De Kruif, J. <i>et al.</i> "Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library," <i>Proc Natl Acad Sci USA</i> (April 1995) 92:3938-3942
AA2	10.	De Kruif, J. <i>et al.</i> "Selection and Application of Human Single Chain Fv Antibody Fragments from a Semi-synthetic Phage Antibody Display Library with Designed CDR3 Regions," <i>J Mol Biol</i> (1995) 248:94-105

EXAMINER:

A. Kruif

DATE CONSIDERED:

5-17-04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

# RECEIVED

PTO/SB/08 (2-92)

Sheet 2 of 4

Form PTO-1449

## INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 313632000801

Application Number 10/039,059

Applicant

TECH CENTER 1600/2900  
Ton LOUENBERG and Cornelia Kruif DE KRUIF

Filing Date December 31, 2001

Group Art Unit 1636

Mailing Date May 23, 2002

11.	Devitt, A. <i>et al.</i> "Human CD14 mediates recognition and phagocytosis of apoptotic cells," <i>Nature</i> (2 April 1998) 392:505-509
12.	Escola, J-M. <i>et al.</i> "Selective Enrichment of Tetraspan Proteins on the Internal Vesicles of Multivesicular Endosomes and on Exosomes Secreted by Human B-lymphocytes," <i>The Journal of Biological Chemistry</i> (August 7, 1998) 279(32):20121-20127
13.	Eshhar, Z. "Tumor-specific T-bodies: towards clinical application," <i>Cancer Immunol Immunother</i> (1997) 45:131-136
14.	Eshhar, Z. <i>et al.</i> "Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the $\gamma$ or $\zeta$ subunits of the immunoglobulin and T-cell receptors," <i>Proc Natl Acad Sci USA</i> (January 1993) 90:720-724
15.	Francisco, J. A. <i>et al.</i> "Transport and anchoring of $\beta$ -lactamase to the external surface of <i>Escherichia coli</i> ," <i>Proc Natl Acad Sci USA</i> (April 1992) 89:2713-2717
16.	Freeman, S. M. <i>et al.</i> "Immune system in suicide-gene therapy," <i>The Lancet</i> (January 4, 1997) 349:2-3
17.	Gage, F. H. "Cell Therapy," <i>Nature</i> (30 April 1998) 392 Supp.:18-24
18.	Ghrayeb, J. <i>et al.</i> "Nine Amino Acid Residues at the NH <sub>2</sub> -terminal of Lipoprotein Are Sufficient for Its Modification, Processing, and Localization in the Outer Membrane of <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> (January 10, 1984) 259(1):463-487
19.	Gong, J. <i>et al.</i> "Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells," <i>Nature Medicine</i> (May 1997) 3(5):558-561
20.	Gosselin, E. J. <i>et al.</i> "Enhanced Antigen Presentation Using Human Fc $\gamma$ Receptor (Monocyte/Macrophage)-Specific Immunogens," <i>The Journal of Immunology</i> (December 1, 1992) 149(14):3477-3481
21.	Graziano, R. F. <i>et al.</i> "Construction and Characterization of a Humanized Anti- $\gamma$ -Ig Receptor Type I (Fc $\gamma$ RI) Monoclonal Antibody," <i>The Journal of Immunology</i> (1995) 155:4996-5002
22.	Grouard, G. <i>et al.</i> "Human Follicular Dendritic Cells Enhance cytokine-Dependent Growth and Differentiation of CD40-Activated B Cells," <i>The Journal of Immunology</i> (1995) 155:3345-3352
23.	Grouard, G. <i>et al.</i> "Human Follicular Dendritic Cells Enhance Cytokine-Dependent Growth and Differentiation of CD40-Activated B Cells," <i>the Journal of Immunology</i> (1995) 155:3345-3352
24.	Haas, C. <i>et al.</i> "An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules," <i>Cancer Gene Therapy</i> (1999) 6(3):254-262
25.	Houghton, A. N. "Cancer Antigens: Immune Recognition of Self and Altered Self," <i>J Exp Med</i> (July 1994) 180:1-4, <i>Commentary</i>
26.	Hwu, P. <i>et al.</i> "In Vivo Antitumor Activity of T Cells Redirected with Chimeric Antibody/T-Cell Receptor Genes," <i>Cancer Research</i> (August 1, 1995) 55:3369-3373
27.	Jin, L. <i>et al.</i> "Targeted expansion of genetically modified bone marrow cells," <i>Proc Natl Acad Sci</i>

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

JUN 06

PTO/SB/08 (2-92)

Sheet 3 of 4

Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 313632000801

Application Number 10/039,059

Applicant

Ton LOGTENBERG and Cornelis Andriaan DE KRUIJF

Filing Date December 31, 2001

Group Art Unit 1636

Mailing Date May 23, 2002

JUN 11 2002

TECH CENTER 1600/2900

USA (July 1998) 95:8093-8097

COPY OF PAPERS  
ORIGINALLY FILED

28. Kafri, T. *et al.* "Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors," *Nature Genetics* (November 1997) 17:314-317, Letter
29. Keene, J-A. *et al.* "Helper Activity is Required for the In Vivo Generation of Cytotoxic T Lymphocytes," *J Exp Med* (March 1982) 155:768-782
30. Kwiatkowska, K. *et al.* "Signaling pathways in phagocytosis," *BioEssays* (1999) 21:422-431
31. Laukkanen, M-L., *et al.* "Functional Immunoliposomes Harboring a Biosynthetically Lipid-Tagged Single-Chain Antibody," *Biochemistry* (1994) 33:11664-11670
32. Laukkanen, M-L., *et al.* "Lipid-tagged antibodies: bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein," *Protein Engineering* (1993) 6(4):449-454
33. Liu, C. *et al.* "FcγRI-Targeted Fusion Proteins Result in Efficient Presentation by Human Monocytes of Antigenic and Antagonist T Cell Epitopes," *J Clin Invest* (November 1996) 98(9):2001-2007
34. Melcher, A. *et al.* "Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression," *Nature Medicine* (May 1998) 4(5):581-587
35. Nawrocki, S. *et al.* "Genetically modified tumour vaccines -- where we are today," *Cancer Treatment Reviews* (1999) 25:29-46
36. Pack, P. *et al.* "Improved Bivalent Miniantibodies, with Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of *E. coli*," *Bio/Technology* (November 1993) 11:1271-1277
37. Ridge, J. P. *et al.* "A conditioned dendritic cell can be a temporal bridge between a CD4<sup>+</sup> T-helper and a T-killer cell," *Nature* (4 June 1998) 393:474-477
38. Rosenberg, S. A. "The Immunotherapy and Gene Therapy of Cancer," *Journal of Clinical Oncology* (February 1992) 10(2):180-199, KARNOFSKY MEMORIAL LECTURE
39. Rosenberg, S. A. *et al.* "Use of tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma, A Preliminary Report," *The New England Journal of Medicine* (Dec. 22, 1988) 319(25):1676-1680, SPECIAL REPORT
40. Rusiñol, A. E. *et al.* "In Vitro Reconstitution of Assembly of Apolipoprotein B48-containing Lipoproteins," *The Journal of Biological Chemistry* (March 21, 1997) 272(12):8019-8025
41. Sallusto, F. *et al.* "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α," *J Exp Med* (April 1994) 179:1109-1118
42. Schirmmacher, V. *et al.* "Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus," *Gene Therapy* (1999) 6:63-73
43. Schoenberger, S. P. *et al.* "T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions," *Nature* (4 June 1998) 393:480-483, Letters to Nature

EXAMINER:

DATE CONSIDERED:

5-17-04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



Form PTO-1449

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 313632000801

Application Number 10/039,059

Applicant

Ton LOGTENBERG and Cornelis Andriaan DE KRUIF

Filing Date December 31, 2001

Group Art Unit ~~444~~ 1636

Mailing Date May 23, 2002

44.	Simons, K. <i>et al.</i> "Functional rafts in cell membranes," <i>Nature</i> (5 June 1997) 387:569-572
45.	Smith, G. P. "Filamentous fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface," <i>Science</i> (14 June 1985) 228:1315-1317
46.	Udenfriend, S. <i>et al.</i> "How Glycosyl-Phosphatidylinositol-Anchored Membrane Proteins are Made," <i>Annu Rev Biochem</i> (1995) 64:563-591
47.	Vermorken, J. B. <i>et al.</i> "Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial," <i>The Lancet</i> (1999) 353:345-50
48.	Yee, C. <i>et al.</i> "Prospects for adoptive T cell therapy," <i>Current Opinion in Immunology</i> (1997) 9:702-708
49.	Zitvogel, L. <i>et al.</i> "Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes," <i>Nature Medicine</i> (May 1998) 4(5):594-600

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

JUN 11 2002

TECH CENTER 1600/2900

EXAMINER:

DATE CONSIDERED:

5-17-04

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.